source
- China-origin biotech deals and IPOs surge as investors reap early returns, while Summit Therapeutics shares slumpBiotech firms built around medicines originating in China have accelerated both acquisitions and initial public offerings this year, according to recent data visualizations. The large pool of Chin…
- Celldex drops eczema antibody barzolvolimab after Phase 2 failureCelldex Therapeutics said it is ending development of its monoclonal antibody barzolvolimab as a treatment for eczema. The Phase 2 study did not show a statistically significant reduction in itchi…